NICE recommends new treatment for rare blood disorder
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
People with chronic primary pain should be offered a range of treatments to help them manage their condition.
One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.
Page 36 of 39